These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28010058)

  • 1. [Epidemiology and risk factors of patients with intra-abdominal postsurgical infection treated with tigecycline: a cohort study].
    Torres G; Paredes M; Hernández A; García C; Sánchez Bueno F; Canteras M; Parrilla P; Gómez J
    Rev Esp Quimioter; 2017 Feb; 30(1):28-33. PubMed ID: 28010058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.
    Heizmann WR; Dupont H; Montravers P; Guirao X; Eckmann C; Bassetti M; García MS; Capparella MR; Simoneau D; Bodmann KF
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii45-55. PubMed ID: 23772046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
    Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C
    Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.
    Eckmann C; Montravers P; Bassetti M; Bodmann KF; Heizmann WR; Sánchez García M; Guirao X; Capparella MR; Simoneau D; Dupont H
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii25-35. PubMed ID: 23772043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections.
    Bartoletti M; Tedeschi S; Pascale R; Raumer L; Maraolo AE; Palmiero G; Tumietto F; Cristini F; Ambretti S; Giannella M; Lewis RE; Viale P
    Int J Antimicrob Agents; 2018 Mar; 51(3):516-521. PubMed ID: 29410250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012.
    Renteria MI; Biedenbach DJ; Bouchillon SK; Hoban DJ; Raghubir N; Sajben P; Mokaddas E
    Diagn Microbiol Infect Dis; 2014 May; 79(1):54-9. PubMed ID: 24582580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A practice-based observational study identifying factors associated with the use of high-dose tigecycline in the treatment of secondary peritonitis in severely ill patients.
    Maseda E; Suárez-de-la-Rica A; Anillo V; Salgado P; Tamayo E; García-Bernedo CA; Ramasco F; Villagrán MJ; López-Tofiño A; Giménez MJ; Granizo JJ; Hernández-Gancedo C; Aguilar L; Gilsanz F
    Rev Esp Quimioter; 2015 Feb; 28(1):47-53. PubMed ID: 25690145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections.
    Maseda E; Denis SE; Riquelme A; Gilsanz F
    Rev Esp Quimioter; 2013 Mar; 26(1):56-63. PubMed ID: 23546465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.
    Falagas ME; Vardakas KZ; Tsiveriotis KP; Triarides NA; Tansarli GS
    Int J Antimicrob Agents; 2014 Jul; 44(1):1-7. PubMed ID: 24602499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital.
    Avkan-Oguz V; Yapar N; Alp-Cavus S; Demir Onder K; Aktas E; Gulay Z; Cakır N
    Int J Clin Pract; 2013 Jun; 67(6):505-11. PubMed ID: 23679904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Tigecycline Compared with Other Broad-Spectrum Antimicrobials in Abdominal Solid Organ Transplant Recipients with Polymicrobial Intraabdominal Infections.
    Liebenstein T; Schulz LT; Viesselmann C; Bingen E; Musuuza J; Safdar N; Rose WE
    Pharmacotherapy; 2017 Feb; 37(2):151-158. PubMed ID: 27983753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Tigecycline Efficacy and Post-Discharge Outcomes in a Clinical Practice Population with Complicated Intra-Abdominal Infection: A Propensity Score-Matched Analysis.
    Solomkin J; Mullins CD; Quintana A; Eckmann C; Shelbaya A; Ernst FR; Krukas MR; Reisman A
    Surg Infect (Larchmt); 2016 Aug; 17(4):402-11. PubMed ID: 26981640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
    Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
    Heizmann WR; Löschmann PA; Eckmann C; von Eiff C; Bodmann KF; Petrik C
    Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
    Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of global intra-abdominal Enterobacteriaceae isolates to tigecycline (TEST 2007-2010).
    Hawser SP; Lob S; Hoban D; Bouchillon S; Badal R
    J Infect; 2012 Jun; 64(6):620-2. PubMed ID: 22326560
    [No Abstract]   [Full Text] [Related]  

  • 19. Tigecycline: an update.
    Stein GE; Babinchak T
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.